ReviewBlood2017
Ethical considerations in genomic testing for hematologic disorders.
Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Who owns that blood? Recontacting donors with results from genetic testing after allogeneic hematopoietic cell transplantation.HemaSphere · 2025Article
- A video intervention to improve patient understanding of tumor genomic testing in patients with cancer.Cancer medicine · 2024Article
- Views of adults living with sickle cell disease on the theoretical return of secondary genomic findings.Genetics in medicine : official journal of the American College of Medical Genetics · 2024Article
- Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort.JCO oncology practice · 2023Review
- Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.Current hematologic malignancy reports · 2022Review
- Ethics Consultation in Oncology: The Search for Quality in Quantity.JCO oncology practice · 2022Article
- Structural Racism in the COVID-19 Pandemic: Don't Forget about the Children!The American journal of bioethics : AJOB · 2021Article
- Informed consent for genetic testing in hematology.Hematology. American Society of Hematology. Education Program · 2020Review
- Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark.Cancers · 2020Article
- Hematological Malignancies in Adults With a Family Predisposition.Deutsches Arzteblatt international · 2018Review
- Ethical conundrums in pediatric genomics.Hematology. American Society of Hematology. Education Program · 2018Review
- Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As our technological capacities improve, genomic testing is increasingly integrating into patient care. The field of clinical hematology is no exception. Genomic testing carries great promise, but several ethical issues must be considered whenever such testing is performed. This review addresses these ethical considerations, including issues surrounding informed consent and the uncertainty of the results of genomic testing; the challenge of incidental findings; and possible inequities in access to and benefit from such testing. Genomic testing is likely to transform the practice of both benign and malignant hematology, but clinicians must carefully consider these core ethical issues in order to make the most of this exciting and evolving technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.